Paper Information

Title: 

EFFECT OF SIMVASTATIN IN COMBINATION WITH ROSIGLITAZONE ON THROMBOEMBOLIC MODEL OF STROKE

Type: POSTER
Author(s): SEIDI S.*,SHAABANZADEH A.R.,PARVIZI M.,KESHAVARZ MANSOUR
 
 *DEPARTMENT OF PHYSIOLOGY, SCHOOL OF MEDICINE, TEHRAN UNIVERSITY OF MEDICAL SCIENCES, TEHRAN, IRAN
 
Name of Seminar: IRANIAN CONGRESS OF PHYSIOLOGY AND PHARMACOLOGY
Type of Seminar:  CONGRESS
Sponsor:  PHYSIOLOGY AND PHARMACOLOGY SOCIETY, MASHHAD UNIVERSITY OF MEDICAL SCIENCE
Date:  2009Volume 19
 
 
Abstract: 

Stroke is a cause of morbidity and mortality and it causes morbidity rather than mortality. For this reason, it imposes huge expenses to the government and social economy annually. Thromboembolic stroke is the most important type of stroke accuring mainly due to occlusion of MCA and its branches. MCA occlusion model by preformed clot is an optimized method in which we can better investigate pathophysiologic status in thromboembolic stroke. In addition, the effect of drugs can be determined or measured. We investigated the effect of simvastatin, rosiglitasone and their combination on stroke rendered by injecting preformed clot in MCA of rat. In this research, we studied three variables including stroke volume, brain edema and motor dysfunctions (neurological deficit) to realize the effect of these drugs. This research showed that rosiglitasone, simvastatin and their combination significantly reduced the stroke volume by 46%, 65% and 78% respectively and brain edema by 23%, 50% and 65% respectively and also improved motor dysfunctions. Combination of these two drugs reduced the infarct volume and brain edema significantly and also improved motor dysfunctions. The amount of stroke volume reduction by simvastatin was not due to brain edema reduction, but it was probably because of other effects such as fibrinolytic, throbmolytic and anti-thrombotic actions in the circulation. The stroke volume and brain edema reduction as well as motor dysfunction improvement by the combination of simvastatin and rosiglitasone is due to their common mechanisms such as activation of peroxisome proliferator-activated receptor gamma (PPARg).

 
Keyword(s): THROMBOEMBOLIC STROKE, MCA, RAT, SIMVASTATIN, ROSIGLITASONE
 
Yearly Visit 7   tarjomyar
 
Latest on Blog
Enter SID Blog